Cargando…

Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports

INTRODUCTION: Purpuric drug eruption (PDE) is an uncommon, clinically distinct side effect of epidermal growth factor receptor (EGFR) inhibitors. PATIENT CONCERNS: Unlike acneiform eruption, which arises from hair follicles mainly in the head and neck area, PDE starts from xerosis cutis, primarily i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Szu-Yun, Wu, Chieh-Shan, Liu, Yi-Shan, Wei, Kai-Che
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882566/ https://www.ncbi.nlm.nih.gov/pubmed/31764850 http://dx.doi.org/10.1097/MD.0000000000018112

Ejemplares similares

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Inflammatory and Purpuric Eruptions
por: Baselga, Eulalia, et al.
Publicado: (2008)

Purpuric eruption in a child
por: Bou-Prieto, Alfredo, et al.
Publicado: (2019)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Unusual purpuric eruption in a child
por: Lin, Jaimie, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab
por: WANG, Mingxia, et al.
Publicado: (2022)

5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review
por: Wang, Shan, et al.
Publicado: (2022)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Purpuric Eruption: Sign of Infected Bypass Graft
por: Ferreira, Joana, et al.
Publicado: (2018)

Purpuric eruption of the breasts, abdomen, thighs, and buttocks
por: Masehi-Lano, Jacqueline J., et al.
Publicado: (2022)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

Palpable purpuric eruption mimicking vasculitis following avapritinib
por: Mohammed, Taha Osman, et al.
Publicado: (2022)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report
por: Liu, Ning, et al.
Publicado: (2021)

Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report
por: Song, Peng, et al.
Publicado: (2017)

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review
por: Falcone, Rosa, et al.
Publicado: (2018)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin
por: Akoglu, Gulsen, et al.
Publicado: (2016)

Generalized papular-purpuric eruption due to Solenopsis fugax bites
por: Romita, Paolo, et al.
Publicado: (2018)

Diffuse purpuric eruption in a patient with acute myeloid leukemia
por: Momin, Zoha K., et al.
Publicado: (2023)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report
por: Yamasaki, Masahiro, et al.
Publicado: (2018)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

Association between polymorphisms of epidermal growth factor 61 and susceptibility of lung cancer: A meta-analysis
por: Chen, Quan, et al.
Publicado: (2020)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Hong, Xiaohua, et al.
Publicado: (2022)

Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China
por: Zhang, Zhihui, et al.
Publicado: (2015)

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review
por: Du, Hong-Juan, et al.
Publicado: (2023)

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
por: Takahashi, Kenta, et al.
Publicado: (2020)

Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
por: Ma, Chunhua, et al.
Publicado: (2020)

Successful treatment of 2 patients with brain metastases from non-small cell lung cancer with epidermal growth factor receptor mutation receiving dacomitinib: A case report
por: Zhao, Songchen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_plcmb4soc2ejlnets24569fk79